Rucaparib Tosylate Crystalline Forms III and V
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Rucaparib, including crystalline Forms III and V of Rucaparib tosylate, to improve processing properties, stability, and bioavailability for cancer treatment, as existing forms may have limitations in compressibility, solubility, and stability.
Innovation Solution
The development of crystalline Forms III and V of Rucaparib tosylate, which can be used to prepare pharmaceutical compositions and formulations for cancer treatment, offering improved properties such as enhanced compressibility, stability, and solubility, and can be combined with pharmaceutically acceptable excipients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If existing solid state forms of Rucaparib are used, then the basic therapeutic function is achieved, but compressibility and tablet manufacturing properties are insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and utilizing different polymorphic forms (Form I, Form II, Form III, Form IV) of Rucaparib tosylate, each with distinct crystal structures and physical properties. These different solid state forms exhibit varying compressibility characteristics, allowing selection of the optimal form for tablet manufacturing. The invention changes the physical state parameters of the API to achieve improved compressibility and manufacturing properties.
2Quantity of substance
If high drug loading is achieved, then therapeutic effectiveness is improved, but tablet size reduction becomes challenging
Solution Approach 1:
The patent utilizes parameter changes in the solid state form of Rucaparib tosylate to achieve high drug loading (45% w/w or more) while maintaining manageable tablet sizes. By selecting polymorphic forms with optimal density and compressibility characteristics, the invention enables concentration of higher API content without proportionally increasing tablet volume, thus resolving the contradiction between drug loading and tablet size.
3Adaptability or versatility
If different salts and solid state forms are used, then formulation flexibility is improved, but stability and shelf-life may vary
Solution Approach 1:
The patent addresses stability concerns by systematically characterizing the stability properties of different polymorphic forms and salts of Rucaparib. Through controlled selection of specific solid state forms with proven stability profiles, the invention maintains chemical stability and shelf-life while preserving formulation flexibility. The patent demonstrates that appropriate parameter selection in solid state form yields both versatility and stability.
4Ease of manufacture
If crystalline forms with improved compressibility are selected, then tablet manufacturing is facilitated, but solubility and dissolution profile may be affected
Solution Approach 1:
The patent resolves the contradiction between compressibility and dissolution by identifying and utilizing polymorphic forms that exhibit favorable balances of both properties. Through systematic evaluation of different crystal forms, the invention selects solid state forms that provide adequate compressibility for manufacturing while maintaining sufficient solubility and dissolution rates for therapeutic effectiveness. This optimized parameter selection achieves both manufacturing facilitation and therapeutic productivity.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Disclosed are solid state forms of Rucaparib and of Rucaparib salts, and pharmaceutical compositions thereof.